Prognostic factors and staging systems of multiple myeloma:. - Concepedia

Concepedia

Publication | Closed Access

Prognostic factors and staging systems of multiple myeloma:.

13

Citations

11

References

2007

Year

Zhongfei Tao, Weijun Fu, Zhen-Gang Yuan, Dongxing Wang, Yubao Chen, Jian Hou

Abstract

High beta(2) microglobulin, high C-reactive protein, low albumin and old age are independent prognostic factors of multiple myeloma. Bataille staging system appears to be optimal for Chinese multiple myeloma patients.

References

	Year	Citations
International Staging System for Multiple Myeloma Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie, Journal of Clinical Oncology	2005	2.9K
Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy Thierry Façon, Hervé Avet‐Loiseau, Gaëlle Guillerm, Blood	2001	313
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system Régis Bataille, Mario Boccadoro, Bernard Klein, Blood	1992	288
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience Joth Jacobson, Mohamad A. Hussein, Bart Barlogie, British Journal of Haematology Cancer ManagementSouthwest Oncology GroupPrognosisPathologyHematological Malignancy	2003	117
Targeting β2-microglobulin for induction of tumor apoptosis in human hematological malignancies Jing Yang, Jianfei Qian, Michele Wezeman, Cancer Cell OncologyMedicineApoptosisHuman Hematological MalignanciesCell Death	2006	95
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors Turesson, Abildgaard, Ahlgren, British Journal of Haematology	1999	58
Why better prognostic factors for multiple myeloma are needed [editorial] [see comments] RA Kyle Blood Prognostic FactorsPrognostic EvaluationHematological MalignancyOncologyPrognosis	1994	57
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients Joan Bladé, Jesús F. San Miguel, M. Fontanillas, The Hematology Journal Hematological MalignancyConventional ChemotherapyMedicineClinical TrialsPathology	2001	57
Immunoglobulin D myeloma – Problems with diagnosing and staging (own experience and literature review) M Kuliszkiewicz-Janus, Anna Zimny, Violetta Sokolska, Leukemia & lymphoma/Leukemia and lymphoma	2005	27
Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma Jae-Pil Yun, Cheolwon Suh, Eun-Kyoung Lee, Journal of Korean Medical Science PathologyPretreatment Sbeta2mLogistic AnalysisMyeloid NeoplasiaHematological Malignancy	2006	12

Page 1